Praluent, a PCSK9 inhibitor by Regeneron and Sanofi, reduced the risk of heart attack, stroke, chest pain and death in a study being presented at the American College of Cardiology's annual meeting. Instead of raising the price, the drug's makers say they will offer insurers and pharmacy benefit managers about a 50% discount for patients with the highest cholesterol levels.
Regeneron, Sanofi offer discount on PCSK9 inhibitor
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.